Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations

Tadahiro Hashita, Yoshihiko Katsuyama, Katsunori Nakamura, Yasuyuki Momose, Daisuke Komatsu, Naohiko Koide, Shinichi Miyagawa, Tomonori Nakamura, Koujirou Yamamoto, Shigeru Ohmori

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In this study we report the pharmacokinetics and severe adverse effects of sunitinib in a woman with a gastrointestinal stromal tumor (GIST). A 60-year-old woman with small intestinal GIST developed severe thrombocytopenia (1.7×10 4/μl) following 1 week of treatment with sunitinib at 50 mg/day. Although the dose of sunitinib was reduced to 25 mg/day, platelet levels remained low. On day 7, the trough concentration of sunitinib plus SU12662 was 46.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng·h/l. The dose was again reduced to 12.5 mg/day. However, the day after resumption of treatment, the patient developed symptoms of left heart failure due to myocardosis caused by sunitinib. Sunitinib has been reported to inhibit platelet-derived growth factor receptor (PDGFR) phosphorylation at concentrations over the range of 50-100 ng/ml (sunitinib plus SU12662) in vivo. In this case, the plasma concentration was sufficient to inhibit PDGFR at 25 or 50 mg/day. However, thrombocytopenia appeared at both dosages. Although the results in this case did not suggest a correlation between thrombocytopenia and plasma concentration, the degree of thrombocytopenia was decreased by reduction of the dose. In conclusion, the findings reported here indicate that the plasma concentration of sunitinib plus SU12662 is an important indicator to reduce adverse effects.

Original languageEnglish
Pages (from-to)501-504
Number of pages4
JournalOncology Letters
Volume4
Issue number3
DOIs
Publication statusPublished - 2012 Sep
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Pharmaceutical Preparations
Thrombocytopenia
Platelet-Derived Growth Factor Receptors
Therapeutics
sunitinib
Area Under Curve
Blood Platelets
Heart Failure
Pharmacokinetics
Phosphorylation

Keywords

  • Gastrointestinal stromal tumor
  • SU12662 (N-desethyl sunitinib)
  • Sunitinib
  • Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hashita, T., Katsuyama, Y., Nakamura, K., Momose, Y., Komatsu, D., Koide, N., ... Ohmori, S. (2012). Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations. Oncology Letters, 4(3), 501-504. https://doi.org/10.3892/ol.2012.779

Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations. / Hashita, Tadahiro; Katsuyama, Yoshihiko; Nakamura, Katsunori; Momose, Yasuyuki; Komatsu, Daisuke; Koide, Naohiko; Miyagawa, Shinichi; Nakamura, Tomonori; Yamamoto, Koujirou; Ohmori, Shigeru.

In: Oncology Letters, Vol. 4, No. 3, 09.2012, p. 501-504.

Research output: Contribution to journalArticle

Hashita, T, Katsuyama, Y, Nakamura, K, Momose, Y, Komatsu, D, Koide, N, Miyagawa, S, Nakamura, T, Yamamoto, K & Ohmori, S 2012, 'Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations', Oncology Letters, vol. 4, no. 3, pp. 501-504. https://doi.org/10.3892/ol.2012.779
Hashita, Tadahiro ; Katsuyama, Yoshihiko ; Nakamura, Katsunori ; Momose, Yasuyuki ; Komatsu, Daisuke ; Koide, Naohiko ; Miyagawa, Shinichi ; Nakamura, Tomonori ; Yamamoto, Koujirou ; Ohmori, Shigeru. / Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations. In: Oncology Letters. 2012 ; Vol. 4, No. 3. pp. 501-504.
@article{d1d76c89b1d240d996b874373e731a73,
title = "Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations",
abstract = "In this study we report the pharmacokinetics and severe adverse effects of sunitinib in a woman with a gastrointestinal stromal tumor (GIST). A 60-year-old woman with small intestinal GIST developed severe thrombocytopenia (1.7×10 4/μl) following 1 week of treatment with sunitinib at 50 mg/day. Although the dose of sunitinib was reduced to 25 mg/day, platelet levels remained low. On day 7, the trough concentration of sunitinib plus SU12662 was 46.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng·h/l. The dose was again reduced to 12.5 mg/day. However, the day after resumption of treatment, the patient developed symptoms of left heart failure due to myocardosis caused by sunitinib. Sunitinib has been reported to inhibit platelet-derived growth factor receptor (PDGFR) phosphorylation at concentrations over the range of 50-100 ng/ml (sunitinib plus SU12662) in vivo. In this case, the plasma concentration was sufficient to inhibit PDGFR at 25 or 50 mg/day. However, thrombocytopenia appeared at both dosages. Although the results in this case did not suggest a correlation between thrombocytopenia and plasma concentration, the degree of thrombocytopenia was decreased by reduction of the dose. In conclusion, the findings reported here indicate that the plasma concentration of sunitinib plus SU12662 is an important indicator to reduce adverse effects.",
keywords = "Gastrointestinal stromal tumor, SU12662 (N-desethyl sunitinib), Sunitinib, Thrombocytopenia",
author = "Tadahiro Hashita and Yoshihiko Katsuyama and Katsunori Nakamura and Yasuyuki Momose and Daisuke Komatsu and Naohiko Koide and Shinichi Miyagawa and Tomonori Nakamura and Koujirou Yamamoto and Shigeru Ohmori",
year = "2012",
month = "9",
doi = "10.3892/ol.2012.779",
language = "English",
volume = "4",
pages = "501--504",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations

AU - Hashita, Tadahiro

AU - Katsuyama, Yoshihiko

AU - Nakamura, Katsunori

AU - Momose, Yasuyuki

AU - Komatsu, Daisuke

AU - Koide, Naohiko

AU - Miyagawa, Shinichi

AU - Nakamura, Tomonori

AU - Yamamoto, Koujirou

AU - Ohmori, Shigeru

PY - 2012/9

Y1 - 2012/9

N2 - In this study we report the pharmacokinetics and severe adverse effects of sunitinib in a woman with a gastrointestinal stromal tumor (GIST). A 60-year-old woman with small intestinal GIST developed severe thrombocytopenia (1.7×10 4/μl) following 1 week of treatment with sunitinib at 50 mg/day. Although the dose of sunitinib was reduced to 25 mg/day, platelet levels remained low. On day 7, the trough concentration of sunitinib plus SU12662 was 46.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng·h/l. The dose was again reduced to 12.5 mg/day. However, the day after resumption of treatment, the patient developed symptoms of left heart failure due to myocardosis caused by sunitinib. Sunitinib has been reported to inhibit platelet-derived growth factor receptor (PDGFR) phosphorylation at concentrations over the range of 50-100 ng/ml (sunitinib plus SU12662) in vivo. In this case, the plasma concentration was sufficient to inhibit PDGFR at 25 or 50 mg/day. However, thrombocytopenia appeared at both dosages. Although the results in this case did not suggest a correlation between thrombocytopenia and plasma concentration, the degree of thrombocytopenia was decreased by reduction of the dose. In conclusion, the findings reported here indicate that the plasma concentration of sunitinib plus SU12662 is an important indicator to reduce adverse effects.

AB - In this study we report the pharmacokinetics and severe adverse effects of sunitinib in a woman with a gastrointestinal stromal tumor (GIST). A 60-year-old woman with small intestinal GIST developed severe thrombocytopenia (1.7×10 4/μl) following 1 week of treatment with sunitinib at 50 mg/day. Although the dose of sunitinib was reduced to 25 mg/day, platelet levels remained low. On day 7, the trough concentration of sunitinib plus SU12662 was 46.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng·h/l. The dose was again reduced to 12.5 mg/day. However, the day after resumption of treatment, the patient developed symptoms of left heart failure due to myocardosis caused by sunitinib. Sunitinib has been reported to inhibit platelet-derived growth factor receptor (PDGFR) phosphorylation at concentrations over the range of 50-100 ng/ml (sunitinib plus SU12662) in vivo. In this case, the plasma concentration was sufficient to inhibit PDGFR at 25 or 50 mg/day. However, thrombocytopenia appeared at both dosages. Although the results in this case did not suggest a correlation between thrombocytopenia and plasma concentration, the degree of thrombocytopenia was decreased by reduction of the dose. In conclusion, the findings reported here indicate that the plasma concentration of sunitinib plus SU12662 is an important indicator to reduce adverse effects.

KW - Gastrointestinal stromal tumor

KW - SU12662 (N-desethyl sunitinib)

KW - Sunitinib

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84863861523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863861523&partnerID=8YFLogxK

U2 - 10.3892/ol.2012.779

DO - 10.3892/ol.2012.779

M3 - Article

VL - 4

SP - 501

EP - 504

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -